Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124936) titled 'A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Condition:
Diffuse Large B Cell Lymphoma (DLBCL)
Intervention:
Drug: HDM2005
Drug: Rituximab or Rituximab biosimilar
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Cyclophosphamide
Drug: Doxorubicin
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of Fir...